ZIOPHARM Oncology (NASDAQ:ZIOP) posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01, Morningstar.com reports.
ZIOP stock opened at $4.28 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.89 and a current ratio of 8.89. ZIOPHARM Oncology has a twelve month low of $1.56 and a twelve month high of $5.00. The firm has a market capitalization of $714.10 million, a price-to-earnings ratio of -8.92 and a beta of 2.64.
A number of research firms have recently commented on ZIOP. HC Wainwright reiterated a “buy” rating and set a $5.50 target price on shares of ZIOPHARM Oncology in a research report on Thursday, May 9th. Zacks Investment Research downgraded ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, May 18th. Lake Street Capital began coverage on ZIOPHARM Oncology in a research report on Thursday, April 4th. They set a “buy” rating and a $7.00 target price for the company. BidaskClub upgraded ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 20th. Finally, Laidlaw assumed coverage on ZIOPHARM Oncology in a report on Monday, April 1st. They set a “buy” rating and a $7.50 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $5.75.
TRADEMARK VIOLATION WARNING: “ZIOPHARM Oncology (ZIOP) Announces Earnings Results, Beats Estimates By $0.01 EPS” was first published by Rockland Register and is owned by of Rockland Register. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://rocklandregister.com/2019/06/01/ziopharm-oncology-ziop-issues-quarterly-earnings-results-beats-estimates-by-0-01-eps.html.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Recommended Story: Trading based on a resistance level
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.